Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer
12 oct. 2016 09h15 HE | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that its amended...
Clearside Logo 2024.jpg
Clearside Biomedical, Inc. to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
10 oct. 2016 07h00 HE | Clearside Biomedical, Inc.
Phase 2 Results in the Treatment of Macular Edema Associated with Retinal Vein Occlusion Phase 2 and Phase 1/2 Results in the Treatment of Macular Edema Associated with Non-Infectious Uveitis ...
Achillion-Logo-150 (4).jpg
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV
23 sept. 2016 11h50 HE | Achillion Pharmaceuticals, Inc.
- ePoster presented today at the EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure - - Ongoing Phase 2 development focusing on triple...
Telemynd.png
Dr. Mark Schiller to present PEER at American College of Private Physicians
22 sept. 2016 05h00 HE | MYnd Analytics, Inc.
LAS VEGAS, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Dr. Mark Schiller, Medical Director - MYnd Analytics, will present “Disruptive Technology Gets Personal” on September 25, 2016 at the Annual...
Pooled Results of Randomized Trials.jpg
MYnd Analytics Letter to Shareholders
21 sept. 2016 08h05 HE | MYnd Analytics, Inc.
MISSION VIEJO, Calif., Sept. 21, 2016 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (OTCQB:CNSO) To our shareholders: We appreciate your continued support. We have produced disruptive results for one...
Ocera Announces Mana
Ocera Announces Management Transition
15 sept. 2016 16h05 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Achillion-Logo-150 (4).jpg
Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV
09 sept. 2016 06h15 HE | Achillion Pharmaceuticals, Inc.
- New data released today in abstract for upcoming EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure - - Janssen advancing triple combination...
Achillion-Logo-150 (4).jpg
Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop
06 sept. 2016 06h05 HE | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of two posters which detailed novel preclinical research into...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer
01 sept. 2016 08h00 HE | OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...
Achillion-Logo-150 (4).jpg
Achillion to Present at Two Upcoming Investor Conferences
01 sept. 2016 06h05 HE | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...